Phase I study of atacicept in relapsed/refractory multiple myeloma (MM) and Waldenström's macroglobulinemia.

No abstract is available for this paper.

• Publication year

  2011

• Venue

  Clinical Lymphoma, Myeloma & Leukemia

• Publication date

  2011-02-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.3816/CLML.2011.n.031PMID 21454215
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• APRIL and TACI interact with syndecan‐1 on the surface of multiple myeloma cells to form an essential survival loop

  2009cited by this paper
• Atacicept in relapsed/refractory multiple myeloma or active Waldenström's macroglobulinemia: a phase I study

  2009cited by this paper
• Phase I Clinical Study of Atacicept in Patients with Relapsed and Refractory B-Cell Non–Hodgkin's Lymphoma

  2008cited by this paper
• Atacicept in patients with rheumatoid arthritis: results of a multicenter, phase Ib, double-blind, placebo-controlled, dose-escalating, single- and repeated-dose study.

  2008cited by this paper
• Atacicept (TACI-Ig) inhibits growth of TACIhigh primary myeloma cells in SCID-hu mice and in coculture with osteoclasts

  2008cited by this paper
• Reduced B lymphocyte and immunoglobulin levels after atacicept treatment in patients with systemic lupus erythematosus: results of a multicenter, phase Ib, double-blind, placebo-controlled, dose-escalating trial.

  2007cited by this paper
• Safety, pharmacokinetics and pharmacodynamics of atacicept in healthy volunteers

  2007cited by this paper
• BAFF and APRIL as osteoclast-derived survival factors for myeloma cells: a rationale for TACI-Fc treatment in patients with multiple myeloma

  2006cited by this paper
• Heparanase influences expression and shedding of syndecan-1, and its expression by the bone marrow environment is a bad prognostic factor in multiple myeloma.

  2006cited by this paper
• B-lymphocyte stimulator (BLyS) stimulates immunoglobulin production and malignant B-cell growth in Waldenstrom macroglobulinemia.

  2006cited by this paper
• Role of B-cell-activating factor in adhesion and growth of human multiple myeloma cells in the bone marrow microenvironment.

  2006cited by this paper
• Heparan sulfate proteoglycan binding promotes APRIL-induced tumor cell proliferation

  2005cited by this paper
• The level of TACI gene expression in myeloma cells is associated with a signature of microenvironment dependence versus a plasmablastic signature.

  2005cited by this paper
• Identification of proteoglycans as the APRIL-specific binding partners

  2005cited by this paper
• Paradoxical increases in serum IgM and viscosity levels following rituximab in Waldenstrom's macroglobulinemia.

  2004cited by this paper
• Expression of BCMA, TACI, and BAFF-R in multiple myeloma: a mechanism for growth and survival.

  2004cited by this paper
• BAFF and APRIL protect myeloma cells from apoptosis induced by interleukin 6 deprivation and dexamethasone.

  2004cited by this paper
• TACI-Ig neutralizes molecules critical for B cell development and autoimmune disease. impaired B cell maturation in mice lacking BLyS.

  2001cited by this paper
• BAFF-R, a Newly Identified TNF Receptor That Specifically Interacts with BAFF

  2001cited by this paper
• Activation molecules on human myeloma cells.

  1999cited by this paper
• BAFF, a Novel Ligand of the Tumor Necrosis Factor Family, Stimulates B Cell Growth

  1999cited by this paper
• NF-AT activation induced by a CAML-interacting member of the tumor necrosis factor receptor superfamily.

  1997cited by this paper
• BCMAp: an integral membrane protein in the Golgi apparatus of human mature B lymphocytes.

  1995cited by this paper

• The BAFF-APRIL System in Cancer

  2023cites this paper
• The Roles of TNF Signaling Pathways in Metabolism of Bone Tumors

  2022cites this paper
• Therapeutic outcome of early-phase clinical trials in multiple myeloma: a meta-analysis

  2021cites this paper
• The TNFSF Members APRIL and BAFF and Their Receptors TACI, BCMA, and BAFFR in Oncology, With a Special Focus in Breast Cancer

  2020cites this paper
• Toward Small-Molecule Inhibition of Protein-Protein Interactions: General Aspects and Recent Progress in Targeting Costimulatory and Coinhibitory (Immune Checkpoint) Interactions.

  2018cites this paper
• Phase 2 study of tabalumab, a human anti‐B‐cell activating factor antibody, with bortezomib and dexamethasone in patients with previously treated multiple myeloma

  2017cites this paper
• Rôle de la molécule APRIL dans le développement des hémopathies malignes B

  2017cites this paper
• Targeted Therapies in Adult B-Cell Malignancies

  2015cites this paper
• Targeted Therapy in Hematological Malignancies: From Basic Research to Clinical Practice

  2015cites this paper
• Myelopoiesis dysregulation associated to sustained APRIL production in multiple myeloma-infiltrated bone marrow

  2015cites this paper
• Novel inhibitors are cytotoxic for myeloma cells with NFkB inducing kinase-dependent activation of NFkB

  2014cites this paper
• Receptor‐Fc and Ligand Traps as High‐Affinity Biological Blockers: Development and Clinical Applications

  2013cites this paper
• Monoclonal antibodies: potential new therapeutic treatment against multiple myeloma

  2013cites this paper
• Clinical targeting of the TNF and TNFR superfamilies

  2013cites this paper
• Pathogenic Long-Lived Plasma Cells and Their Survival Niches in Autoimmunity, Malignancy, and Allergy

  2012cites this paper
• Therapeutic approaches to myeloma bone disease: an evolving story.

  2012cites this paper
• Immunosuppressive monoclonal antibodies: current and next generation.

  2011cites this paper
• Malignancy, and Allergy Their Survival Niches in Autoimmunity, Pathogenic Long-lived Plasma Cells And

  year unknowncites this paper